These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 24607494

  • 1. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
    Rauscher J, Beschorner R, Gierke M, Bisdas S, Braun C, Ebner FH, Schittenhelm J.
    J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
    [Abstract] [Full Text] [Related]

  • 2. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.
    Jones DT, Mulholland SA, Pearson DM, Malley DS, Openshaw SW, Lambert SR, Liu L, Bäcklund LM, Ichimura K, Collins VP.
    Acta Neuropathol; 2011 Jun; 121(6):753-61. PubMed ID: 21327941
    [Abstract] [Full Text] [Related]

  • 3. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
    van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Idbaih A, Sanson M, Smitt PA, French PJ.
    Clin Cancer Res; 2011 Nov 15; 17(22):7148-55. PubMed ID: 21914791
    [Abstract] [Full Text] [Related]

  • 4. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
    Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR.
    Chin Med J (Engl); 2010 Dec 15; 123(24):3566-73. PubMed ID: 22166632
    [Abstract] [Full Text] [Related]

  • 5. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
    Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G.
    Acta Neuropathol; 2016 Feb 15; 131(2):309-319. PubMed ID: 26493382
    [Abstract] [Full Text] [Related]

  • 6. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW.
    Cancer; 2012 Jan 15; 118(2):452-60. PubMed ID: 21717448
    [Abstract] [Full Text] [Related]

  • 7. MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.
    Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Bäcklund LM, Collins VP, Ichimura K.
    Int J Cancer; 2012 Sep 01; 131(5):1104-13. PubMed ID: 22020830
    [Abstract] [Full Text] [Related]

  • 8. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A.
    Acta Neuropathol; 2010 Dec 01; 120(6):707-18. PubMed ID: 21088844
    [Abstract] [Full Text] [Related]

  • 9. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
    Capper D, Mittelbronn M, Meyermann R, Schittenhelm J.
    Acta Neuropathol; 2008 Feb 01; 115(2):249-59. PubMed ID: 17965865
    [Abstract] [Full Text] [Related]

  • 10. [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].
    Wick W, Weller M.
    Nervenarzt; 2010 Aug 01; 81(8):928-30, 932-5. PubMed ID: 20635074
    [Abstract] [Full Text] [Related]

  • 11. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
    Gorlia T, Delattre JY, Brandes AA, Kros JM, Taphoorn MJ, Kouwenhoven MC, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, van den Bent MJ.
    Eur J Cancer; 2013 Nov 01; 49(16):3477-85. PubMed ID: 23896377
    [Abstract] [Full Text] [Related]

  • 12. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R, Atli Eİ, Özdemir M, Çiftçi E, Aydin HE, Artan S, Arslantaş A.
    Gene; 2015 Jan 01; 554(1):81-6. PubMed ID: 25455102
    [Abstract] [Full Text] [Related]

  • 13. Unveiling hierarchy and spatial distribution of O6-methylguanine-DNA methyltransferase promoter methylation in World Health Organization grade 2-3 gliomas.
    Li M, Liu J, Weng J, Dong G, Chen X, Cui Y, Ren X, Shen S, Jiang H, Zhang X, Zhao X, Li M, Wang X, Ren H, Li Q, Zhang Y, Cheng Q, Yu Y, Lin S.
    Cancer Sci; 2024 Oct 01; 115(10):3403-3414. PubMed ID: 39101880
    [Abstract] [Full Text] [Related]

  • 14. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study.
    Abd El-Hafez A, Ismail Hany HSED.
    Asian Pac J Cancer Prev; 2020 Aug 01; 21(8):2403-2413. PubMed ID: 32856872
    [Abstract] [Full Text] [Related]

  • 15. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
    Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.
    J Neurooncol; 2012 May 01; 107(3):617-31. PubMed ID: 22287028
    [Abstract] [Full Text] [Related]

  • 16. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A.
    Acta Neuropathol; 2008 Dec 01; 116(6):597-602. PubMed ID: 18985363
    [Abstract] [Full Text] [Related]

  • 17. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
    Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, Beroukhim R, Hornick JL, Alexander BM, Ligon KL, Ramkissoon SH.
    Oncotarget; 2014 Sep 30; 5(18):8083-92. PubMed ID: 25257301
    [Abstract] [Full Text] [Related]

  • 18. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
    Ammendola S, Caldonazzi N, Simbolo M, Piredda ML, Brunelli M, Poliani PL, Pinna G, Sala F, Ghimenton C, Scarpa A, Barresi V.
    Virchows Arch; 2021 Nov 30; 479(5):987-996. PubMed ID: 34165590
    [Abstract] [Full Text] [Related]

  • 19. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas.
    Koos B, Peetz-Dienhart S, Riesmeier B, Frühwald MC, Hasselblatt M.
    Neuropathol Appl Neurobiol; 2010 Jun 30; 36(4):356-8. PubMed ID: 20202118
    [No Abstract] [Full Text] [Related]

  • 20. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
    Rajmohan KS, Sugur HS, Shwetha SD, Ramesh A, Thennarasu K, Pandey P, Arivazhagan A, Santosh V.
    J Clin Pathol; 2016 Aug 30; 69(8):686-94. PubMed ID: 26743027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.